iShares US Pharmaceuticals ETFIHE
IHE
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
5% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 43
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
1% less funds holding
Funds holding: 141 [Q2] → 140 (-1) [Q3]
2.56% less ownership
Funds ownership: 59.2% [Q2] → 56.64% (-2.56%) [Q3]
7% less capital invested
Capital invested by funds: $403M [Q2] → $374M (-$29.3M) [Q3]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for IHE.
Financial journalist opinion
Positive
Zacks Investment Research
1 week ago
ETFs Poised to Win or Lose Under Trump's New Policies
Donald Trump commences his second term by enacting a series of executive orders. The actions are poised to create winners and losers across different industries.
Positive
ETF Trends
2 weeks ago
New Year's Resolutions: Lose Weight & Allocate to GLP-1 ETFs
For many of us, a new year often means a new chance to start fresh in our battle with weight. Thanks to interesting ETF product development, especially in the past year, it could also mean a chance to consider the investment opportunity in weight loss as a theme.
Neutral
Zacks Investment Research
1 month ago
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on 05/01/2006.
Neutral
Seeking Alpha
2 months ago
IHE Contraction Is Not Justified By Fundamental Data
iShares U.S. Pharmaceuticals ETF is a pharmaceutical ETF offered by iShares, featuring an expense ratio of 0.39% and over $500 million in assets under management. In Q3, the healthcare sector reported earnings that exceeded expectations (+9.3%) and provided strong guidance for CV 2025, according to FactSet. The IHE prices are down 10% from their all-time high, with the next point of control 20% lower, while the maximum drawdown in the past 10 years was 40%.
Neutral
Zacks Investment Research
3 months ago
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on 05/01/2006.
Neutral
Zacks Investment Research
5 months ago
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Launched on 05/01/2006, the iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.
Positive
Zacks Investment Research
5 months ago
Pharma ETFs in Focus Post Solid Q2 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Neutral
ETF Trends
5 months ago
Disruptive Theme of the Week: Playing Defense
When markets correct, it is a good time to revisit which equity market sectors are “defensive” themes. Certain products and services are nondiscretionary in nature that we cannot live without.
Neutral
Seeking Alpha
6 months ago
IHE: Significant Growth Ahead, But Valuation Not Cheap (Rating Downgrade)
IHE invests in large-cap U.S. pharmaceutical stocks with solid long-term growth outlook but high concentration risk. IHE's fund price has been steady with a positive trend in 2024, but its elevated valuation may not make it a good buy currently. Despite being a defensive play in an economic recession, IHE can still experience significant declines due to market sentiment.
Neutral
Zacks Investment Research
7 months ago
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on 05/01/2006.
Charts implemented using Lightweight Charts™